Across TCGA pan-cancer cohorts, U2AF1L4 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated U2AF1L4 data layer compared with 28 for mass-spec protein and 4 for mutation status.
The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher U2AF1L4 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated U2AF1L4 expression acts as an unfavorable survival marker.
PDAC are the cancer types where U2AF1L4 mass-spec protein most reproducibly stratifies survival.